Express Scripts named a Top Pick for 2014 at Mizuho Mizuho named Express Scripts a top pick for 2014 due to improving company fundamentals, catalysts that include initial 2014 guidance, sell-side target increases, and upcoming investor day. Shares are Buy rated with a price target of $86.
Express Scripts CEO says Gilead relationship 'important' going forward Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.